Journal
AMERICAN JOURNAL OF HEMATOLOGY
Volume 87, Issue 4, Pages 392-400Publisher
WILEY
DOI: 10.1002/ajh.23110
Keywords
-
Categories
Funding
- NIH [K08 DK075846, RO1 DK087727, RO1 DK069533, RO1 DK071837]
- Massachusetts General Hospital
Ask authors/readers for more resources
Anemia of chronic disease (ACD) or anemia of inflammation is prevalent in patients with chronic infection, autoimmune disease, cancer, and chronic kidney disease. ACD is associated with poor prognosis and lower quality of life. Management of ACD using intravenous iron and erythropoiesis stimulating agents are ineffective for some patients and are not without adverse effects, driving the need for new alternative therapies. Recent advances in our understanding of the molecular mechanisms of iron regulation reveal that increased hepcidin, the iron regulatory hormone, is a key factor in the development of ACD. In this review, we will summarize the role of hepcidin in iron homeostasis, its contribution to the pathophysiology of ACD, and novel strategies that modulate hepcidin and its target ferroportin for the treatment of ACD. Am. J. Hematol. 2012. (C) 2011 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available